class="enumerated" style="list-style-type:decimal">The effects of inhibitors of nitric oxide synthase (NOS) on the responsiveness of the human nasal airway were investigated, by measuring the nasal response to histamine and bradykinin.Repeated intranasal administration of NG-nitro-L-arginine methyl ester (L-NAME) or NG-monomethyl-L-arginine (L-NMMA), 1 μmol per nostril every 30 min for 6 h, increased the nasal obstruction induced by histamine, 50–500 μg, and bradykinin, 200 μg per nostril. A single administration of L-NAME, 1 μmol per nostril did not induce hyperresponsiveness to histamine.Pretreatment with L-arginine, 30 μmol, abolished the hyperresponsiveness to histamine caused by L-NAME, 1 μmol. Pretreatment with NG-nitro-D-arginine methyl ester (D-NAME), 1 μmol, did not induce hyperresponsiveness to histamine.Repeated administration of L-NAME, 1 μmol, caused a significant reduction in the amount of nitric oxide measured in the nasal cavity.Neither L-NMMA, 1 μmol, nor L-arginine, 30 μmol, altered the nasal hyperresponsiveness induced by platelet activating factor (PAF), 60 μg. PAF did not alter the levels of nitric oxide in the nasal cavity.The results suggest that inhibition of nitric oxide synthase induces a hyperresponsiveness in the human nasal airway, and that this occurs by a mechanism different from that involved in PAF-induced hyperresponsiveness.
展开▼
机译：class =“ enumerated” style =“ list-style-type：decimal”> <！-list-behavior =枚举前缀-word = mark-type = decimal max-label-size = 0-> 通过测量鼻腔内对组胺和缓激肽的反应，研究了一氧化氮合酶（NOS）抑制剂对人鼻道反应的影响。 重复鼻内施用N G sup>-硝基-L-精氨酸甲酯（L-NAME）或N G -单甲基-L-精氨酸（L-NMMA），每鼻孔每30μmin1μmol，持续6μh，组胺（50-500μg）和缓激肽（200μg/鼻孔）引起的鼻阻塞。一次施用L-NAME，每个鼻孔1μlmol不会诱导对组胺的高反应性。 用30μμl的L-精氨酸预处理可以消除1μμmol的L-NAME对组胺的高反应性。用N G -硝基-D-精氨酸甲酯（D-NAME）预处理1μμmol，不会诱导对组胺的高反应性。 L-NAME的重复给药（1） μmol导致鼻腔中一氧化氮的含量显着降低。 L-NMMA（1μμmol）和L-精氨酸（30μμmol）均未改变由血小板活化因子引起的鼻腔反应过度（PAF），60μg。 PAF并没有改变鼻腔中一氧化氮的水平。 结果表明，抑制一氧化氮合酶会诱发人鼻气道高反应性，这是通过与所涉及机制不同的机制发生的PAF引起的反应过度。
展开▼
